FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBiogen Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BIIB
Biogen Inc. Stock AnalysisComprehensive stock analysis for Biogen Inc. (BIIB) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBIIB
BIIB
Biogen Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BIIB
  1. Home
  2. Stocks
  3. Biogen Inc.

Biogen Inc.

🇺🇸BIIB•NASDAQ

Biogen Inc.

🇺🇸BIIB•NASDAQ
Market cap
$37.20B
Sentiment

Your view on BIIB

Mkt Cap
$37.20B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Biogen Inc.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Christopher A. Viehbacher
Headquarters
225 Binney Street, Cambridge, MA, US
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Christopher A. Viehbacher
Headquarters
225 Binney Street, Cambridge, MA, US
Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.

It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.

In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.

Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development.

The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Biogen Inc. from FRC's valuation model, read against the market price. BIIB last traded at $251.65, 106.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Biogen Inc.. Starting points for Biogen Inc.: P/E 106.8, EPS $2.35, beta 0.17 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Biogen Inc.. Biogen Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Biogen Inc.. Trailing twelve-month EPS for Biogen Inc. stands at $2.35. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$252.64

average of 28 firms, last 12 months

 

$252.64

Low $175.00

Median $253.00

High $325.00

 

Analyst Ratings

Buy24 firms, last 12 months
  • Strong Buy0
  • Buy16
  • Hold7
  • Sell1
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$2.79$3.55$12.51$16.23
Low estimate$2.50$2.92$12.07$8.66
High estimate$3.28$4.03$13.08$19.01
No. of analysts1892021
Year-ago EPS$1.99$3.57$8.79—
Growth+40.1%-0.5%+42.3%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$2.61B$2.63B$10.60B$10.80B
Low estimate$2.45B$2.51B$10.36B$10.37B
High estimate$3.33B$2.71B$11.40B$11.16B
No. of analysts1782626
Year-ago revenue$2.28B$2.48B$9.89B—
Growth+14.4%+6.2%+7.2%—
Recent analyst actions15 rating and price-target changes, latest Nov 9, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Biogen Inc.. Biogen Inc. has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BIIB19 companies · 8 funds
Compare BIIB with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ALNYAlnylam Pharmaceuticals, Inc.Biotechnology$21.4B
  • AMGNAmgen Inc.Drug Manufacturers - General$250.1B
  • AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
  • IONSIonis Pharmaceuticals, Inc.Biotechnology$4.7B
  • LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
  • PFEPfizer Inc.Drug Manufacturers - General$164.5B
  • PTCTPTC Therapeutics, Inc.Biotechnology$5.1B
  • REGNRegeneron Pharmaceuticals, Inc.Biotechnology$98.5B

More Drug Manufacturers - General companies

  • ORINYOrion OyjOTC$22.8B
  • OTSKFOtsuka Holdings Co., Ltd.OTC$35.4B
  • OTSKYOtsuka Holdings Co., Ltd.OTC$36.6B
  • PFE.NEPfizer Inc.NEO
  • PTKFFPT Kalbe Farma Tbk.OTC$3.2B
  • PTKFYPT Kalbe Farma Tbk.OTC$15M
  • RHHBFRoche Holding AGOTC$390.8B
  • RHHBYRoche Holding AGOTC$383.1B
  • RHHVFRoche Holding AGOTC$386.4B
  • SCLXScilex Holding CompanyNASDAQ$9M
  • SCLXWScilex Holding CompanyNASDAQ$7M

ETFs holding Biogen Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.06%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.05%
  • VOVanguard Mid-Cap ETF$103.4B in assets0.36%
  • IVViShares Core SP 500 ETF$852.9B in assets0.06%
  • PBEInvesco Biotechnology & Genome ETF$438M in assets5.85%
  • FTXHFirst Trust Nasdaq Pharmaceuticals ETF$1.2B in assets3.95%
  • FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.69%
  • PJPInvesco Pharmaceuticals ETF$600M in assets3.48%

Largest holders first, then the funds most concentrated in BIIB.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Biogen Inc., and how their positions are changing. At a $37.20B market value, institutional positions materially move Biogen Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Biogen Inc. executives and directors. Shares of Biogen Inc. have traded between $110.04 and $170.78 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Biogen Inc.. Biogen Inc. is a $37.20B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Biogen Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Biogen Inc.. Coverage tracks Biogen Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Biogen Inc.

BIIB Analysis
Fair
Past5
Growth1
Health3
Profit1
Value1

News

Latest Market News